Form 4: Sage Therapeutics Executive Gregory Shiferman Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations following the vesting of restricted stock units.
Summary
- On February 13, 2025, Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, reported the vesting of restricted stock units (RSUs).
- A total of 376 shares were withheld at a price of $7.18 to cover tax obligations related to the vesting of 1,125 RSUs granted on February 13, 2023.
- An additional 251 shares were withheld at a price of $7.18 to cover tax obligations related to the vesting of 750 RSUs granted on February 13, 2024.
- Following these transactions, Shiferman beneficially owns 33,261 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The disclosure provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| November 1, 2024 | Date of Power of Attorney authorization for Chris Benecchi, Brandon Marsh, and Stuart Falber to act on Gregory L. Shiferman's behalf for SEC filings. |
| February 13, 2023 | Date of grant for 1,125 time-based restricted stock units (RSUs) that vest 25% on each grant anniversary date over four years. |
| February 13, 2024 | Date of grant for 750 time-based restricted stock units (RSUs) that vest 25% on each grant anniversary date over four years. |
| February 13, 2025 | Date of transaction: vesting of RSUs and withholding of shares for tax obligations. |
| February 14, 2025 | Date of signature on the Form 4 report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.